Model Introduction
QGP-1 is a well-characterized human pancreatic neuroendocrine tumor (pNET) cell line originally established from a liver metastatic lesion of a patient with non-functional pancreatic neuroendocrine carcinoma. This cell line retains the well-differentiated neuroendocrine phenotype of pNET, expressing core neuroendocrine biomarkers including chromogranin A (CgA), synaptophysin (Syn) and neuron-specific enolase (NSE), and retains the ability to secrete measurable CgA into culture supernatant. The subcutaneous xenograft mouse model established with QGP-1 cells is a widely used preclinical in vivo model for pancreatic neuroendocrine tumor research, extensively applied in anti-tumor drug screening, somatostatin analog evaluation, targeted therapy research, peptide receptor radionuclide therapy (PRRT) preclinical validation and nanoparticle delivery system studies. Different from pancreatic ductal adenocarcinoma (PDAC) models, QGP-1 xenografts exhibit relatively slow growth, lower proliferative index and stable neuroendocrine differentiation, closely recapitulating the indolent but progressive clinical course of well-differentiated pNET.
Experimental Principle
Immunodeficient BALB/c nude mice lack mature functional T lymphocytes and cannot mount effective cellular immune rejection against human-derived tumor xenografts. After harvesting QGP-1 cells in logarithmic growth phase and preparing a single-cell suspension, the suspension is subcutaneously inoculated into the dorsal flank of recipient mice. Tumor cells progressively proliferate in subcutaneous tissue and recruit host stromal vasculature, forming well-circumscribed solid tumor masses with neuroendocrine differentiation. By regularly measuring tumor volume, body weight, serum CgA level and imaging-based tumor burden, researchers can quantitatively assess in vivo neuroendocrine tumor growth kinetics and evaluate the anti-tumor efficacy of test compounds, biological agents or combination regimens.
Model Identification & Detection Indicators
- Tumor volume measurement: Starting from the day of visible tumor formation, the longest tumor diameter (L) and shortest diameter (W) are measured every 2–3 days using a vernier caliper. Tumor volume is calculated by the formula: TV (mm³) = 0.5 × L × W².
- Body weight monitoring: Body weight of each mouse is recorded synchronously with tumor volume measurement, serving as an indicator of systemic toxicity induced by tumor burden or drug treatment.
- Serum CgA monitoring: Periodic blood collection from the facial vein or tail vein is performed, and serum CgA concentration is quantified by human CgA ELISA kit. Rising serum CgA level serves as a non-invasive surrogate biomarker for neuroendocrine tumor burden.
- Model success criteria: The expected tumor formation rate of the QGP-1 subcutaneous xenograft model is ≥80%. When tumor volume reaches 100–150 mm³ at approximately day 21–28 post inoculation, the model is considered successfully established and eligible for randomized grouping and therapeutic intervention.
- Histopathological verification: At the experimental endpoint, tumor tissues are excised, fixed in 4% paraformaldehyde and embedded in paraffin. H&E staining confirms organoid or trabecular neuroendocrine tumor morphology. Immunohistochemistry detects biomarkers including chromogranin A, synaptophysin, Ki-67 and somatostatin receptor 2 (SSTR2) to verify neuroendocrine differentiation, proliferative activity and receptor expression.
Model Advantages
- QGP-1 is one of the few well-characterized human pNET cell lines, retaining authentic neuroendocrine differentiation with stable CgA and synaptophysin expression, providing high translational relevance for pNET research.
- The model supports both caliper-based tumor volume measurement and serum CgA ELISA monitoring, enabling dual-modal non-invasive pharmacodynamic readouts.
- QGP-1 xenografts express SSTR2, supporting preclinical evaluation of somatostatin analogs, peptide receptor radionuclide therapy (PRRT) and SSTR-targeted imaging agents.
- The relatively slow and stable tumor growth kinetics are suitable for long-term efficacy studies of chronic therapeutic regimens such as biotherapy, targeted therapy and metronomic chemotherapy.
Application Scenarios
- In vivo anti-tumor activity evaluation of small-molecule compounds, chemotherapeutic agents (e.g., streptozocin, temozolomide, capecitabine) and targeted drugs (e.g., everolimus, sunitinib) against pNET.
- Preclinical pharmacodynamic assessment of somatostatin analogs (e.g., octreotide, lanreotide), peptide receptor radionuclide therapy (PRRT) and SSTR-targeted imaging or therapeutic conjugates.
- Mechanistic research on neuroendocrine tumor proliferation, secretion regulation, anti-apoptotic signaling and mTOR pathway activation.
- Preliminary in vivo efficacy screening prior to orthotopic pancreatic neuroendocrine tumor model or patient-derived xenograft (PDX) model studies.
Zvast Biotechnology
